Please ensure Javascript is enabled for purposes of website accessibility

FDA Approves Eli Lilly's Trulicity to Reduce Cardiovascular Events in Type 2 Diabetes Patients

By Brian Orelli, PhD – Feb 24, 2020 at 1:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The approval should help the big pharmaceutical fight off competition from other drugs in the same class.

The Food and Drug Administration has expanded the approval of Eli Lilly's (LLY 8.14%) Trulicity to include its use for the reduction of major adverse cardiovascular events in patients with type 2 diabetes who have established cardiovascular disease or multiple risk factors for developing cardiovascular issues.

The drug has been approved to treat patients with type 2 diabetes since 2014, but this label expansion makes Trulicity the first drug for type 2 diabetes approved for both preventing or managing risk factors and for reducing the risk of another event occurring.

The approval was based on the REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) study, which followed patients treated with Trulicity for a median of 5.4 years. The drug reduced the risk of major cardiovascular events such as heart attacks and strokes by 12%. The pharmaceutical company showed Trulicity worked equally well in patients with established cardiovascular disease as it did in patients who only had cardiovascular risk factors: a 13% reduction in events for both groups.

Hands using a glucose monitor

Image source: Getty Images.

Trulicity is a GLP-1 receptor agonist, and has become the most-prescribed drug in its class, in large part because it only has to be injected once a week. But Eli Lilly's investors need to be looking in the over their shoulders at Novo Nordisk (NVO 3.27%), which gained FDA approval of an oral GLP-1 drug, Rybelsus, last year.

Rybelsus has some data on its label showing the drug might reduce cardiovascular events, but the patients in its studies were only followed for two years. Novo Nordisk sells the same active ingredient in Rybelsus as Ozempic, which needs to be injected, but it remains to be seen whether doctors will extrapolate the more robust cardiovascular events data from Ozempic to Rybelsus.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$336.42 (8.14%) $25.32
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
$99.04 (3.27%) $3.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.